Edwards Lifesciences closed the second quarter of 2026 with an operating story that largely worked and a tax story that did not. On the operating side, worldwide net sales reached $1.74 billion for the quarter ended June 30, 2026, a 13.6% increase from the same period in 2025, paced by double-digit growth in the transcatheter aortic valve replacement franchise and a near-50% surge in the newer transcatheter mitral and tricuspid therapies segment. The company also secured several regulatory clearances that broaden its addressable market, including CE Mark for the SAPIEN M3 RESILIA mitral system, FDA approval for the TRIFORMIS RESILIA surgical tricuspid valve, and FDA 510(k) clearance for the ECLIPTIS left atrial appendage technology. Those approvals suggest the product pipeline is converting from development milestones to commercial catalysts at a moment when investors are looking for the next leg of growth beyond the mature TAVR market.
Operating income expanded impressively. The company reported operating income of $513.2 million in the second quarter, up from $411.2 million in the prior-year period, reflecting operating leverage across the transcatheter businesses. Yet the headline net income attributable to Edwards Lifesciences fell to $241.9 million from $333.2 million a year earlier, and diluted earnings per share dropped to $0.42 from $0.56. The gap between strong operating performance and weaker bottom-line results came almost entirely from tax. A California budget law enacted on June 29, 2026 forced Edwards to record a $188.2 million valuation allowance against deferred tax assets, pushing the second-quarter effective tax rate to 53.6% versus 16.1% in the prior-year period. The result is a quarter that looks better on a pre-tax basis than on a per-share basis, which is the central tension for the stock at its current valuation.
The read on the quarter is that the core structural heart business remains healthy, but earnings quality is under pressure from non-operating items. The market appears to be pricing Edwards as a steady-growth medtech compounder with a forward price-to-earnings multiple near 27 times, a figure that embeds expectations for sustained double-digit revenue growth and eventual margin recovery. The question is whether tax and foreign-exchange headwinds are transitory enough to allow operating performance to shine through, or whether they are more likely to compress the multiple until the company demonstrates cleaner earnings.
The load-bearing risk is a combination of regulatory and commercial disappointment in TMTT, where expectations are highest, and further tax or tariff escalation that masks operational progress. The next test arrives with third-quarter results, when investors can see whether the new product approvals translate into procedure volumes and whether the tax rate normalizes toward prior-year levels. If the company can deliver sequential operating-margin improvement alongside a more stable tax outlook, confidence in the forward multiple should hold. Otherwise, the stock is likely to trade sideways until 2027 guidance introduces a cleaner comparison baseline.